SORAYA Trial Data with Dr. Ursula A. Matulonis-Presentation Recording

Video Transcription

Video Summary

The video is a presentation of the results of the SEREA trial, which evaluated the efficacy and safety of a drug called Mervectuximab in patients with platinum-resistant ovarian cancer. The presentation is given by Dr. Ursula Matalonos, the Chief of Division of Gynecological Oncology at Dana-Farber Cancer Institute. The trial enrolled patients with high expression of the protein folate receptor alpha (FR-alpha) and had received prior treatment with bevacizumab. The primary endpoint of the trial was the overall response rate, which was found to be 32.4%. Complete responses were observed in 5% of patients. The median duration of response was 6.9 months. The drug was well-tolerated, with most adverse events being low-grade and reversible. Ocular events, such as blurred vision, were observed but managed with supportive care measures. The results suggest that Mervectuximab has potential as a biomarker-driven standard of care treatment for patients with FR-alpha positive platinum-resistant ovarian cancer. The presentation also mentions upcoming IGCS educational programs and the annual global meeting in September. The video provides valuable information about the Sirea trial and its implications for the treatment of platinum-resistant ovarian cancer.

Keywords

SEREA trial

Mervectuximab

platinum-resistant ovarian cancer

Dr. Ursula Matalonos

folate receptor alpha

overall response rate

complete responses